Dr. Lydon’s interest in S. aureus started following a hospital infection his partner contracted during an orthopedic procedure on her leg. A serious case of osteomyelitis nearly cost her the use of her leg. This experience led him to begin to explore possible new bio-therapeutic approaches to the treatment of S. aureus infections and to found Staurus Pharma to pursue this work.  The technology he developed involved the use of Fc modified humanized anti-S. aureus antibodies.  


He understood that the key advantages of developing an antibody that inhibits Protein A include an expected low rate of emergence of bacterial resistance and increased potency. He also expects that they may also complement antibiotics in the management of immunocompromised patients.  In addition, mAbs have significantly longer half-lives providing compliance advantages (single dose) and less toxicity to the normal body flora.